---
granola_id: 97d22f42-9e6b-4c39-a75d-b5c830870612
title: "Virtue / Dart"
type: note
created: 2025-12-09T18:30:18.029Z
updated: 2025-12-10T04:37:39.311Z
attendees:
  - aakruti@darthealthai.com
  - sd@virtuevc.com
  - veeraj@darthealth.ai
---
### Current Business Performance & 2026 Strategy

- $2M ARR still on track with strong monthly growth trajectory
	- $300-350K monthly recurring revenue run rate
	- CHAP accreditation body validation secured for credibility
	- Offsite productive for strategic vision planning through 2026
- Product consolidation and focus areas
	- Moving from 50+ disparate features to single unified product offering
	- Clinical data analytics as core wedge targeting CNOs and CMOs specifically
	- Patient quality and compliance with deeper query capabilities for actionable insights
	- Cost and margin optimization critical for scaling intelligence/reasoning features
- Revenue expansion model and targets
	- 80-90% of current customer base convertible to expansion deals
	- End of 2026 goal: blow past $10M ARR milestone
	- Expansion within health systems identified as huge leading signal
	- Focus on larger whale accounts vs basic blocking and tackling approach

### Go-to-Market & Team Building

- Sales team expansion with strategic hire
	- Kelly joining from HomeHealth 100 background with relevant experience
	- Part-time arrangement structured for $4-5M annual quota capacity
	- Decision driven by candidate availability rather than budget constraints
	- Expected to free up founder bandwidth while scaling post-acute care segment
- Health system pipeline development
	- Beth Israel patient safety initiative progressing to Jan/Feb implementation timeline
	- Strong momentum with existing health system accounts
	- Repositioning strategy for health systems requiring dedicated team buildup
- Critical engineering and product hires

### Investment & Strategic Partnerships Discussion

- Current fundraising process managed strategically
	- Seeking $2M+ round with investors bringing deep bio/life science domain expertise
	- Not optimizing purely for price or highest valuation
	- Looking for strategic value-add beyond standard introductions and Rolodex access
	- Ali (founder) maintaining control over timing and investor selection criteria
- Virtue team guidance and support
	- Term sheet evaluation for standard vs non-standard terms
	- Strategic hiring recommendations and network introductions
	- Reference checks and process management assistance
	- Founder coaching on fundraising approach and investor fit
- Partnership evaluation with larger players
	- Feedback collection from national and regional health system players
	- Validation of commercial viability path important for future investors
	- TBD on specific partnership structures and timeline

### Action Items

- Ali: Continue fundraising conversations with bio/life science focused investors (ongoing)
- Ali: Finalize Kelly onboarding and quota structure for sales role (next 1-2 weeks)
- Team: Execute Beth Israel patient safety implementation (Jan/Feb 2025)
- Ali: Define head of engineering hire requirements and begin search (Q1 2026)
- Virtue team: Provide additional investor introductions with domain expertise (TBD timing)
- Ali: Collect feedback from national/regional health system partners on product fit (Q1 2026)
- Team: Complete product consolidation from 50+ features to unified offering (end of 2026)
- Virtue team: Schedule follow-up call to review fundraising progress and next steps (TBD)

Chat with meeting transcript: https://notes.granola.ai/t/1e56d41f-836d-46bc-ac00-c20aa4a0206d
